header logo image


Page 41«..1020..40414243..5060..»

Archive for the ‘Biotechnology’ Category

Review of George Estreich, ‘Fables and Futures: Biotechnology, Disability, and the Stories We Tell Ourselves’ (opinion) – Inside Higher Ed

Wednesday, November 20th, 2019

A few months ago, I attended a forum on the politics and economics of disability. My impression was that the audience consisted mainly of people with disabilities -- an impression that has changed with time. Whatever the proportions may actually have been, my judgment was probably skewed by self-consciousness, and not just the usual awkwardness of finding a seat after the presentation was well underway. It had taken root long before I got to the room.

"Able-bodied" and "disabled" are categories that function in society at large as necessary and common-sensical, and they are weighted such that the first is posited as normal and predominant, and as such effectively invisible, while the other is an exceptional condition, making it, oddly, both conspicuous and ignorable as circumstances may dictate. With hindsight I am not at all sure more people at the talk had wheelchairs or canes than were present at other talks I attended at the conference. Besides, not every disability involves such a clear marker.

But since disability itself was the topic of the hour, the fact that I did not need any such assistance registered much more sharply than it ordinarily would. Eyeglasses didn't count. Experiential norms prevailing outside the room were not taken for granted, as became even more clear following the speaker's presentation. A number of people pointed out that no American Sign Language interpreter was present. Somehow I had not noticed. Not noticing certain things is a luxury you generally aren't even aware of enjoying.

As binary oppositions go, "able-bodied/disabled" proves much less stable than it appears. It's not just that the most gifted athlete or graceful dancer may be one bullet or automobile accident away from an irrevocable change in status. As mentioned, wearing glasses allows me to function as fully able, but they are a prosthesis for the lenses in my eyes, quite as much a wheelchair is for a paraplegic's legs. And the process of aging has a way of erasing the bright line between ability and its malfunctions. Time is not on the side of the able-bodied. With aging, the binary opposition runs right through the brain, so to speak. Jokes about "having a senior moment" acknowledge (and deflect) this reality. Our long-term command of the powers of attention and memory is contingent at best.

One of the things the reader can take away from George Estreich's Fables and Futures: Biotechnology, Disability, and the Stories We Tell Ourselves (MIT Press) is a heightened sense of how damaging it can be to think of "the disabled" in terms of a distinction between "us" and "them." An instructor in writing at Oregon State University, Estreich is also the author of The Shape of an Eye: A Memoir, about raising his daughter Laura, who has Down syndrome. I haven't read it, but she reappears throughout Fables and Futures without that making the book a memoir, exactly.

"Writing about Laura has its complications," Estreich notes. "For each sentence, I could add a page of narrative caveats, a fine print to govern the legal interpretation of anecdote: 'This positive description is not meant to inspire Though the author has strong opinions on a range of social issues, he declines to weaponize his daughter in their service. Laura is not an example in an argument She is a person, and by describing her the author intends to suggest what she is like and raise questions about the world she enters. This work is related to, yet different from, his work as a parent, which is to help her find, in every sense, her place.' Behind these caveats is the wish to control interpretation, and behind that vain hope is, in no particular order, a writer's ego, a father's protectiveness, and a deep familiarity with the average Internet comment section."

That is quite a few knives to juggle at the same time. And the list does not even include the issue on which Estreich concentrates here: the advancing biotechnology of prenatal testing and genetic editing. The book is a sort of intellectual travelogue, the author thinking his way across a landscape that is changing faster than it can be captured in concepts. When he attends an event in New Orleans that doubles as a professional conference for genetic counselors and a trade show for biotech companies, he notes, "The uneasy tension between old and new brought on by biotech: the more artifice the project requires, the more its advocates retail images of naturalness and purity." The quest to render the woolly mammoth "de-extinct" coexists with strong an implicit and largely unacknowledged strain of 21st-century eugenics.

Given the murderous consequences of one especially vehement form, we tend to think of eugenics as prone to goose-stepping. But a tangent from the memory of his daughter's participation in a county fair leads Estreich back to the era of Better Babies and Fitter Families contests at Midwestern state fairs, in which whole families underwent exams and answered questionnaires to determine which was freest from inherited defects. "If human improvement is on stage," he writes, "disability-based metaphors are usually skulking in the wings."

The author's worry -- which is also a father's worry -- concerns the possible cascade of effects of "our rapidly increasing, fine-grained knowledge of genetic variation." A culture that takes technological development as inevitable is dangerous enough, to itself and others, without having the option of decision making that "invoke[s] abnormality, a word capacious enough to hold everything and everyone considered different and undesirable." Estreich is uncommonly adept at presenting both experiences and ideas in layers, without the structure itself becoming either unmanageable or distracting. Anyone who reads it should expect the wheels in their head to keep spinning for a while afterward.

Read the original post:
Review of George Estreich, 'Fables and Futures: Biotechnology, Disability, and the Stories We Tell Ourselves' (opinion) - Inside Higher Ed

Read More...

Immunic, Inc. Expands Board of Directors with Appointment of Biotechnology Executive Barclay A. Phillips – P&T Community

Wednesday, November 20th, 2019

NEW YORK, Nov. 19, 2019 /PRNewswire/ --Immunic, Inc. (Nasdaq: IMUX),a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced the appointment of Barclay "Buck" A. Phillips, an established life sciences executive, investor and entrepreneur, to its Board of Directors, effective November 14, 2019. With this addition, Immunic's Board will total seven members.

"Buck's decades of relevant experience in the biotechnology sector, both as a Chief Financial Officer and investor, will add a unique perspective to our Board," stated Duane Nash, M.D., J.D., M.B.A., Chairman of the Board of Directors of Immunic. "We look forward to leveraging his significant expertise in the areas of financing strategy, capital markets, business development, and others, which he has garnered during his successful career as an executive and board member for multiple, Nasdaq-listed life science companies. Buck's addition to our team reflects our desire to build the Board during a time of continued clinical progress and we look forward to his contributions."

Until recently, Mr. Phillips was Chief Financial Officer and Senior Vice President of Corporate Development at G1 Therapeutics, Inc., where, among other achievements, he was instrumental in raising over USD 300 million in multiple equity financings. Before that, he served as Senior Vice President, Chief Financial Officer and Treasurer of vaccine company, Novavax, Inc., where he helped to raise more than USD 850 million in various financings to support the company's late-stage clinical programs. Prior, Mr. Phillips was Senior Vice President and Chief Financial Officer of Micromet, Inc., which, during his tenure, was acquired by Amgen Inc. for approximately USD 1.2 billion. Mr. Phillips's exposure to venture capital came earlier, while serving as a Managing Director at Vector Fund Management, focused on investments in late-stage life sciences companies, and during his time as Biotechnology Analyst and Director of Venture Investments at Invesco, where he held primary coverage responsibility for the universe of publicly traded biotechnology companies, while managing the firm's private equity investing, with a focus on life sciences.

Mr. Phillips has served on the boards of over a dozen public and private life sciences companies. He earned a Bachelor of Arts in economics from the University of Colorado at Boulder.

About Immunic, Inc.Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including relapsing-remitting multiple sclerosis, ulcerative colitis, Crohn's disease, and psoriasis. The company is developing three small molecule products: IMU-838 is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORt; and IMU-856 targets the restoration of the intestinal barrier function. Immunic's lead development program, IMU-838, is in phase 2 clinical development for relapsing-remitting multiple sclerosis and ulcerative colitis, with an additional phase 2 trial planned in Crohn's disease. An investigator-sponsored proof-of-concept clinical trial for IMU-838 in primary sclerosing cholangitis is ongoing at the Mayo Clinic. For further information, please visit: http://www.immunic-therapeutics.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Immunic's clinical and preclinical pipeline activities and the structure and composition of its board. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management's current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient resources to meet business objectives and operational requirements, the fact that the results of earlier studies and trials may not be predictive of future clinical trial results, the protection and market exclusivity provided by Immunic's intellectual property, risks related to the drug development and the regulatory approval process and the impact of competitive products and technological changes. A further list and descriptions of these risks, uncertainties and other factors can be found in the section captioned "Item 1A. Risk Factors," in the company's Current Report on Form 8-K filed on July 17, 2019, and in the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at http://www.sec.gov or ir.immunic-therapeutics.com/sec-filings. Any forward-looking statement made in this release speaks only as of the date of this release. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all the contents of this press release.

Contact Information

Immunic, Inc.Jessica BreuManager IR and Communications+49 89 250 0794 69jessica.breu@immunic.de

Or

Rx Communications GroupMelody Carey+1-917-322-2571immunic@rxir.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/immunic-inc-expands-board-of-directors-with-appointment-of-biotechnology-executive-barclay-a-phillips-300960819.html

SOURCE Immunic, Inc.

Read more from the original source:
Immunic, Inc. Expands Board of Directors with Appointment of Biotechnology Executive Barclay A. Phillips - P&T Community

Read More...

Exclusive Research on Biotechnology-Based Chemical Market by CMFE Insights with Leading Players Sarnia-Lambton Research, UK and Norway business…

Wednesday, November 20th, 2019

Biotechnology-Based Chemical Market are items gotten from natural roots, for example, feedstock, plants, harvests, trees, and organic waste. This will benefit the reports users, that evaluates their position in the market as well as create effective strategies in the near future. They are a reasonable option in contrast to traditional synthetic concoctions and will assume a noteworthy job in decreasing the dependence on non-renewable energy sources. This can prompt diminished carbon discharge levels and keep up the biological parity. Lignocellulose is the most generally accessible crude material utilized for the creation of biofuels.

The report of CMFE Insights the Industrial substance application is foreseen to command the worldwide Biotechnology-Based Chemical Market growing CAGR of +16% during forecast period.

The report shields the development activities in the Biotechnology-Based Chemical which includes the status of marketing channels available, and an analysis of the regional export and import. The report ends with an inference for the global market as it was in industry. Researchers of this research report throw light on demand-supply chaining in the market. The forward-disapproved of people supporting the improvement of bio-based synthetic substances, specialists have been growing new sources and applications for Biotechnology-Based Chemical Market around the globe, delivering promising outcomes.

Request A sample copy of this report at https://www.cmfeinsights.com/request-sample.php?id=46666

The Report includes Several Company Profiles of who are market key players:

Biotechnology-Based Chemical Market by region:

The significant sorts of biotechnology are red, green, white, and blue biotechnology. Red biotechnology includes medicinal procedures, white biotechnology which is otherwise called dark biotechnology is primarily utilized in mechanical procedures, green biotechnology includes agrarian biotech procedures and blue biotechnology involves marine and amphibian procedures. Biotechnology-Based Chemical Market has wide applications crosswise over modern territories, for example, horticulture, prescription, sustenance generation, human services, and yield creation.

Get up to 40% Discount on this report at https://www.cmfeinsights.com/ask-for-discount.php?id=46666

Market by Type

Market by Application

The application, of worldwide Biotechnology-Based Chemical Market compounds is isolated into mechanical synthetic compounds, agribusiness, pharmaceuticals, and others. Leading key players have been profiled to get a clear insight into the businesses on the basis of successful strategies of the top level companies. Along with this, it also offers competitive significance among the several traders by presenting the facts and figures of market shares.

In this study, the years considered to estimate the market size of Biotechnology-Based Chemical Market are as follows:

About Us : CMFE Insights caters to clients needs by elucidating the power of innovation, thus thriving on business innovations. Our mission is to guide global businesses through our comprehensive market research reports. Through our infrastructural competence of digital transformations, we orchestrate escalated market efficiency for our clients by presenting them with capable growth opportunities in the global market scenario. Through the experienced eye of our research associates we help our clients to envision a flourishing future. CMFE Insights techniques is a perfect blend of both qualitative and quantitative modes, on basis of which we provide our clients with syndicated research reports to further enhance their strategic organizational decisions. CMFE Insights helps clients to build a pragmatic future in the innovative market industry.

Contact :

CMFE Insights

Jay S

+44 7537 121342

Office 271

321 323 High Rd

Chadwell Heath

RM6 6AX UK

sales@cmfeinsights.com

http://www.cmfeinsights.com

Read more:
Exclusive Research on Biotechnology-Based Chemical Market by CMFE Insights with Leading Players Sarnia-Lambton Research, UK and Norway business...

Read More...

Women in Biotech: Katz Event Explores the Rewards and Challenges of a Career in Biotechnology – Yu News

Wednesday, November 20th, 2019

From the gene-editing powers of CRISPR-Cas9 to the creation of clean meat technologies, the biotechnology field continues to top one new development with another in rapid succession, and because of this innovative velocity, there is an increasing need for biotech leaders who understand both the science and the business of this ever-expanding field.

Where do women fit into this process? Do they face the same gender parity issues that they confront in other areas of science, technology, engineering and math, or STEM? What challenges should they prepare for as they launch a career in biotech?

A top-notch panel of scientists and entrepreneurs came together on Sept. 26, 2019, to answer these questions at the Katz School of Science and Healths first fall event for Women in Bio. Leading Biotech and Healthcare Organizations from Early to Late Stage, was co-organized by Dr. Rana Khan, director of the MS in Biotechnology Management and Entrepreneurship Program at the Katz School, and the New York Chapter of Women in Bio, the national organization for women in life sciences.

Panelists included Dr. Christina Brennan, vice president of clinical research, Northwell Health; Dr. Jeanne Magram, chief scientific officer, Quentis Therapeutics; Dr. Sandra Saldana, CEO and co-founder of Alva Health and adjunct professor at Yeshiva University; and Dr. Mani Mohindru, CFO and chief strategy officer at Cara Therapeutics.

The event was a resounding success with great speakers and engaged attendees, one of whom described it as a difference-making experience. It was empowering to sit in a roomful of professional women, in top roles, opening their hearts about the challenges they are going through. I came away with two new connections that are meaningful to my career. Thank you, YU, for hosting such a memorable event.

Original post:
Women in Biotech: Katz Event Explores the Rewards and Challenges of a Career in Biotechnology - Yu News

Read More...

Cellect Biotechnology Reports Third Quarter 2019 Financial and Operating Results – PRNewswire

Wednesday, November 20th, 2019

TEL AVIV, Israel, Nov. 19, 2019 /PRNewswire/ --Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of innovative technology which enables the functional selection of stem cells, today reported financial and operating results for the third quarter ended September 30, 2019 and provided a corporate update.

Recent Highlights

"Our clinical and regulatory teams remained focused during the third quarter and the more recent positive developments position us to achieve our goals, both in the U.S. and Israel," commented Dr. Shai Yarkoni, Chief Executive Officer. "In the U.S., the IND approval is a significant achievement and represents our first-ever FDA IND in the U.S., with Washington University School of Medicine. In Israel, our Phase 1/2 clinical study of ApoGraft is progressing slowly and we expect to complete the recruitment around the end of the year."

"With our prudent use of cash during the third quarter and the anticipated cash usage needs over the coming quarters, we continue to believe we have the resources to execute our clinical and regulatory plans for the foreseeable future," said Eyal Leibovitz, Chief Financial Officer.

ThirdQuarter 2019 Financial Results:

*For the convenience of the reader, the amounts above have been translated from NIS into U.S. dollars, at the representative rate of exchange on September 30, 2019 (U.S. $1 = NIS 3.482).

Strategic Review Progress Update

On May 16, 2019, the Company disclosed that it commenced plans to explore strategic alternatives to maximize shareholder value. Potential strategic alternatives that may be evaluated include, but are not limited to, an acquisition, merger, business combination, including in other business fields than the Company's in-licensing, or other strategic transaction involving the Company or its assets. The Company continues to evaluate business development opportunities and will keep investors informed as they mature or warrant investor disclosure.

About Cellect Biotechnology Ltd.

Cellect Biotechnology (APOP) has developed a breakthrough technology, for the selection of stem cells from any given tissue, that aims to improve a variety of stem cell-based therapies.

The Company's technology is expected to provide researchers, clinical community and pharma companies with the tools to rapidly isolate stem cells in quantity and quality allowing stem cell-based treatments and procedures in a wide variety of applications in regenerative medicine. The Company's current clinical trial is aimed at bone marrow transplantations in cancer treatment.

Forward Looking Statements

This press release contains forward-looking statements about the Company's expectations, beliefs and intentions. Forward-looking statements can be identified by the use of forward-looking words such as "believe", "expect", "intend", "plan", "may", "should", "could", "might", "seek", "target", "will", "project", "forecast", "continue" or "anticipate" or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In addition, historical results or conclusions from scientific research and clinical studies do not guarantee that future results would suggest similar conclusions or that historical results referred to herein would be interpreted similarly in light of additional research or otherwise. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: the Company's history of losses and needs for additional capital to fund its operations and its inability to obtain additional capital on acceptable terms, or at all; the Company's ability to continue as a going concern; or maintain its current operations; uncertainties involving any strategic transaction the Company may decide to enter into as the result of its current efforts to explore new strategic alternatives; uncertainties of cash flows and inability to meet working capital needs; the Company's ability to obtain regulatory approvals; the Company's ability to obtain favorable pre-clinical and clinical trial results; the Company's technology may not be validated and its methods may not be accepted by the scientific community; difficulties enrolling patients in the Company's clinical trials; the ability to timely source adequate supply of FasL; risks resulting from unforeseen side effects; the Company's ability to establish and maintain strategic partnerships and other corporate collaborations; the scope of protection the Company is able to establish and maintain for intellectual property rights and its ability to operate its business without infringing the intellectual property rights of others; competitive companies, technologies and the Company's industry; unforeseen scientific difficulties may develop with the Company's technology; and the Company's ability to retain or attract key employees whose knowledge is essential to the development of its products. Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in Cellect Biotechnology Ltd.'s Annual Report on Form 20-F for the fiscal year ended December 31, 2018 filed with the U.S. Securities and Exchange Commission, or SEC, which is available on the SEC's website, http://www.sec.gov, and in the Company's periodic filings with the SEC.

Cellect Biotechnology Ltd

Consolidated Statement of Operation

Convenience

translation

Nine months

ended

Nine months ended

Three months ended

September 30,

September 30,

September 30,

2019

2019

2018

2019

2018

Unaudited

Unaudited

U.S. dollars

NIS

(In thousands, except share and per

share data)

Research and development expenses

2,743

9,551

9,473

2,465

4,125

General and administrative expenses

2,249

7,832

11,001

2,768

3,929

Operating loss

4,992

17,383

20,474

5,233

8,054

Financial expenses (income) due to warrants exercisable into shares

(2,303)

(8,020)

(2,935)

(910)

(1,320)

Other financial expenses (income), net

393

1,369

(1,177)

489

64

Total comprehensive loss

3,082

10,732

16,362

4,812

6,798

Loss per share:

Basic and diluted loss per share

0.015

0.051

0.127

0.021

0.052

Basic and diluted loss per ADS

0.30

1.02

2.54

0.42

1.04

Weighted average number of shares outstanding used to compute basic and diluted loss per share

208,771,303

208,771,303

129,139,278

224,087,799

130,192,799

Cellect Biotechnology Ltd.

Consolidated Balance Sheet Data

ASSETS

Convenience

translation

September 30,

September 30,

December 31,

2019

2019

Here is the original post:
Cellect Biotechnology Reports Third Quarter 2019 Financial and Operating Results - PRNewswire

Read More...

Food Biotechnology Market 2019| 2019 Applications, Types and Growing Trends, Share 2024 – Eastlake Times

Wednesday, November 20th, 2019

The global Food Biotechnology industry research report offers a detailed analysis of the current status of the market 2019. This extensive Global Food Biotechnology Market research report contains a brief on industry trends that can guide the business operators in the industry to get an idea of the market and strategize for their business development accordingly. The research report studies the market size, Food Biotechnology industry share, growth rate, key segments, CAGR (%) and key drivers. At the start, the report offers a basic introduction to the Food Biotechnology market including definitions, applications, classifications and industry chain analysis. The study serves as the international Food Biotechnology market consist of development past, competitive landscape study, and advancement states of Food Biotechnology in major geographical regions.

Get a sample of the report from https://www.orbisreports.com/global-food-biotechnology-market/?tab=reqform

Secondly, Food Biotechnology manufacturing processes and cost study are discussed as well as development policies and plans are also included. This Food Biotechnology market research report also gives the data on import/send out, supply-demand, and Food Biotechnology consumption values along with cost, revenue and gross margin by worldwide regions. This Food Biotechnology report will surely help you to understand and apply the ideas and guide you in making strong decisions. The world Food Biotechnology industry was valued in 2019 is XX Mn US$ and is evaluates to be XX Mn US$ forecasting to 2024, with a perspective CAGR of X.X %.

Food Biotechnology Market Major Manufacturers:

ABS GlobalArcadia BiosciencesAquaBounty TechnologiesBASF Plant ScienceBayer CropScience AGCamson Bio Technologies LtdDow AgroSciences LLCDuPont PioneerEvogene LtdHy-Line InternationalKWS GroupMonsantoOrigin Agritech LimitedSyngenta AG

The aim of Food Biotechnology report is to give an idea to the readers in making firm business decisions based on market latest trends and upcoming market improvement estimates in forecast years. The study contains Food Biotechnology market contributors including vendors/traders, buyers/distributors/, suppliers/sellers. Their Food Biotechnology marketing strategies are also provided. Global Food Biotechnology report analyses the historical data regarding the market growth, Food Biotechnology market scope and also offers the current and Food Biotechnology market upcoming information. The study of major growth opportunities and challenges to the Food Biotechnology market is included.

Food Biotechnology Market Types Are:

Transgenic CropsSynthetic Biology Derived Products

Food Biotechnology Market Applications Are:

AnimalsPlantsOther

For more Information or Any Query Visit: https://www.orbisreports.com/global-food-biotechnology-market/?tab=discount

The worldwide Food Biotechnology industry report offers a thorough study of the Food Biotechnology market. The report Food Biotechnology focuses industry vision from experts. An in-depth segmentation of the Food Biotechnology industry has been provided in the report. Moreover, the world Food Biotechnology industry report also includes the sub-segments. The key sector, the emerging and leading sectors, together with their growth stats have been cited in the Food Biotechnology market report.

After a brief outlook of the global Food Biotechnology market, the report studies the market dynamics. The major drivers helping Food Biotechnology market growth and the major constraints inhibiting Food Biotechnology market growth are provided in this report. In addition, the Food Biotechnology industry report also gives the threats and challenges that companies in the Food Biotechnology market need to focus on. The most influencing trends that will give the structure the Food Biotechnology market during the forecasting prospect are also provided in this report. Furthermore, the report expands on the regulatory scheme governing the Food Biotechnology market and its possible effects on the market in the foreseeable horizon.

The insight analysis on Food Biotechnology research report provides:

The evaluated Food Biotechnology growth rate together with size and market share over the forecast period 2019-2024. The primary factors estimated to drive the Food Biotechnology Market for the forecasting period 2019-2024. The major Global Food Biotechnology market regulatory bodies and what has been their business expanding strategy for leading so far. Influential trends shaping the growth probabilities of the Food Biotechnology Market.

In-depth and complete business outlook, Food Biotechnology market revenue study, business expansion strategies, and SWOT analysis of the major leading players have been served in the report. Vendors in the Worldwide Food Biotechnology market are focusing to explore their operations to developing regions. More, companies in the Food Biotechnology market are concentrating on innovation and standing their Food Biotechnology products at competitive prices. A detailed analysis of Food Biotechnology supply chain in the report will help readers to understand Food Biotechnology market clearly.

Click here to see full TOC https://www.orbisreports.com/global-food-biotechnology-market/?tab=toc

Read the original here:
Food Biotechnology Market 2019| 2019 Applications, Types and Growing Trends, Share 2024 - Eastlake Times

Read More...

Where Does JNCE Stock Rank in the Biotechnology Industry? – InvestorsObserver

Wednesday, November 20th, 2019

The 74 rating InvestorsObserver gives to Jounce Therapeutics Inc (JNCE) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 96 percent of stocks in the Biotechnology industry, JNCEs 74 overall rating means the stock scores better than 74 percent of all stocks.

Click Here to get the full Stock Score Report on Jounce Therapeutics Inc (JNCE) Stock.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Jounce Therapeutics Inc (JNCE) stock is trading at $5.81 as of 10:05 AM on Thursday, Nov 14, a rise of $0.22, or 3.86% from the previous closing price of $5.59. The stock has traded between $5.62 and $6.19 so far today. Volume today is 195,167 compared to average volume of 163,071.

To see InvestorsObservers Sentiment Score for Jounce Therapeutics Inc click here.

Read the original post:
Where Does JNCE Stock Rank in the Biotechnology Industry? - InvestorsObserver

Read More...

PDS Biotechnology (NASDAQ:PDSB) Will Have To Spend Its Cash Wisely – Yahoo Finance

Wednesday, November 20th, 2019

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, biotech and mining exploration companies often lose money for years before finding success with a new treatment or mineral discovery. Nonetheless, only a fool would ignore the risk that a loss making company burns through its cash too quickly.

So should PDS Biotechnology (NASDAQ:PDSB) shareholders be worried about its cash burn? For the purpose of this article, we'll define cash burn as the amount of cash the company is spending each year to fund its growth (also called its negative free cash flow). The first step is to compare its cash burn with its cash reserves, to give us its 'cash runway'.

View our latest analysis for PDS Biotechnology

A company's cash runway is the amount of time it would take to burn through its cash reserves at its current cash burn rate. As at September 2019, PDS Biotechnology had cash of US$17m and such minimal debt that we can ignore it for the purposes of this analysis. Looking at the last year, the company burnt through US$12m. So it had a cash runway of approximately 17 months from September 2019. That's not too bad, but it's fair to say the end of the cash runway is in sight, unless cash burn reduces drastically. The image below shows how its cash balance has been changing over the last few years.

NasdaqCM:PDSB Historical Debt, November 12th 2019

Because PDS Biotechnology isn't currently generating revenue, we consider it an early-stage business. So while we can't look to sales to understand growth, we can look at how the cash burn is changing to understand how expenditure is trending over time. Remarkably, it actually increased its cash burn by 673% in the last year. With that kind of spending growth its cash runway will shorten quickly, as it simultaneously uses its cash while increasing the burn rate. Clearly, however, the crucial factor is whether the company will grow its business going forward. So you might want to take a peek at how much the company is expected to grow in the next few years.

While PDS Biotechnology does have a solid cash runway, its cash burn trajectory may have some shareholders thinking ahead to when the company may need to raise more cash. Generally speaking, a listed business can raise new cash through issuing shares or taking on debt. Commonly, a business will sell new shares in itself to raise cash to drive growth. We can compare a company's cash burn to its market capitalisation to get a sense for how many new shares a company would have to issue to fund one year's operations.

PDS Biotechnology has a market capitalisation of US$15m and burnt through US$12m last year, which is 85% of the company's market value. That suggests the company may have some funding difficulties, and we'd be very wary of the stock.

Even though its cash burn relative to its market cap makes us a little nervous, we are compelled to mention that we thought PDS Biotechnology's cash runway was relatively promising. Considering all the measures mentioned in this report, we reckon that its cash burn is fairly risky, and if we held shares we'd be watching like a hawk for any deterioration. For us, it's always important to consider risks around cash burn rates. But investors should look at a whole range of factors when researching a new stock. For example, it could be interesting to see how much the PDS Biotechnology CEO receives in total remuneration.

Story continues

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies, and this list of stocks growth stocks (according to analyst forecasts)

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.

Read the original:
PDS Biotechnology (NASDAQ:PDSB) Will Have To Spend Its Cash Wisely - Yahoo Finance

Read More...

Where Does FTSV Stock Rank in the Biotechnology Industry? – InvestorsObserver

Wednesday, November 20th, 2019

The 59 rating InvestorsObserver gives to Forty Seven Inc (FTSV) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 81 percent of stocks in the Biotechnology industry, FTSVs 59 overall rating means the stock scores better than 59 percent of all stocks.

Click Here to get the full Stock Score Report on Forty Seven Inc (FTSV) Stock.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Forty Seven Inc (FTSV) stock is trading at $10.31 as of 10:05 AM on Thursday, Nov 14, a rise of $0.12, or 1.18% from the previous closing price of $10.19. The stock has traded between $10.28 and $10.57 so far today. Volume today is below average. So far 51,681 shares have traded compared to average volume of 211,996 shares.

To see InvestorsObservers Sentiment Score for Forty Seven Inc click here.

Visit link:
Where Does FTSV Stock Rank in the Biotechnology Industry? - InvestorsObserver

Read More...

Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? – Yahoo Finance

Sunday, November 10th, 2019

Looking for broad exposure to the Healthcare - Biotech segment of the equity market? You should consider the Invesco Dynamic Biotechnology & Genome ETF (PBE), a passively managed exchange traded fund launched on 06/23/2005.

Passively managed ETFs are becoming increasingly popular with institutional as well as retail investors due to their low cost, transparency, flexibility and tax efficiency. They are excellent vehicles for long term investors.

Sector ETFs also provide investors access to a broad group of companies in particular sectors that offer low risk and diversified exposure. Healthcare - Biotech is one of the 16 broad Zacks sectors within the Zacks Industry classification. It is currently ranked 2, placing it in top 13%.

Index Details

The fund is sponsored by Invesco. It has amassed assets over $227.92 M, making it one of the average sized ETFs attempting to match the performance of the Healthcare - Biotech segment of the equity market. PBE seeks to match the performance of the Dynamic Biotechnology & Genome Intellidex Index before fees and expenses.

This is comprised of stocks of 30 U.S. biotechnology and genome companies. These are companies that are principally engaged in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes and companies that benefit significantly from scientific and technological advances in biotechnology and genetic engineering and research.

Costs

Expense ratios are an important factor in the return of an ETF and in the long term, cheaper funds can significantly outperform their more expensive counterparts, other things remaining the same.

Annual operating expenses for this ETF are 0.57%, making it on par with most peer products in the space.

Sector Exposure and Top Holdings

While ETFs offer diversified exposure, which minimizes single stock risk, a deep look into a fund's holdings is a valuable exercise. And, most ETFs are very transparent products that disclose their holdings on a daily basis.

This ETF has heaviest allocation in the Healthcare sector--about 100% of the portfolio.

Looking at individual holdings, Biogen Inc (BIIB) accounts for about 6.52% of total assets, followed by Vertex Pharmaceuticals Inc (VRTX) and Celgene Corp (CELG).

The top 10 holdings account for about 49.20% of total assets under management.

Performance and Risk

The ETF has added roughly 10.04% so far this year and is down about -3.11% in the last one year (as of 11/05/2019). In that past 52-week period, it has traded between $43.44 and $56.26.

The ETF has a beta of 1.43 and standard deviation of 23.63% for the trailing three-year period, making it a high risk choice in the space. With about 30 holdings, it has more concentrated exposure than peers.

Alternatives

Invesco Dynamic Biotechnology & Genome ETF carries a Zacks ETF Rank of 3 (Hold), which is based on expected asset class return, expense ratio, and momentum, among other factors. Thus, PBE is a reasonable option for those seeking exposure to the Health Care ETFs area of the market. Investors might also want to consider some other ETF options in the space.

SPDR S&P Biotech ETF (XBI) tracks S&P Biotechnology Select Industry Index and the iShares Nasdaq Biotechnology ETF (IBB) tracks Nasdaq Biotechnology Index. SPDR S&P Biotech ETF has $3.81 B in assets, iShares Nasdaq Biotechnology ETF has $7.02 B. XBI has an expense ratio of 0.35% and IBB charges 0.47%.

Bottom Line

To learn more about this product and other ETFs, screen for products that match your investment objectives and read articles on latest developments in the ETF investing universe, please visit Zacks ETF Center.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportInvesco Dynamic Biotechnology & Genome ETF (PBE): ETF Research ReportsiShares Nasdaq Biotechnology ETF (IBB): ETF Research ReportsSPDR S&P Biotech ETF (XBI): ETF Research ReportsCelgene Corporation (CELG) : Free Stock Analysis ReportVertex Pharmaceuticals Incorporated (VRTX) : Free Stock Analysis ReportBiogen Inc. (BIIB) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research

Read the original post:
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? - Yahoo Finance

Read More...

Goodwin Biotechnology Launches a Digitization Initiative by Investing in a Sophisticated Electronic Quality Solution – Yahoo Finance

Sunday, November 10th, 2019

FORT LAUDERDALE, Fla., Nov. 6, 2019 /PRNewswire/ --Goodwin Biotechnology, Inc. announced that it has recently licensed an industry leading electronic content and document management solution to enhance the efficiency and effectiveness of its Quality systems and operations. This improvement continues to ensure that Goodwin Biotechnology remains uniquely positioned as aqualified and flexible biopharmaceutical Contract Development and Manufacturing Organization (CDMO) that offers an integrated Single Source Solution from Cell Line Development, Process Development and cGMP manufacturing including Scale-Up, cGMP Contract Manufacturing, and Aseptic Fill / Finish of mammalian cell-culture derived monoclonal antibodies, recombinant proteins, vaccines, and Antibody Drug Conjugates (ADCs).

"Acquisition and implementation of this sophisticated electronic solution demonstrates Goodwin's commitment to providing top-tier development and manufacturing services for our clients," noted Karl Pinto, Chief Executive Officer at Goodwin Biotechnology. "Goodwin's past successes supporting our clients through their early- and late-stage clinical trials, and regulatory compliant commercial manufacturing, will be strengthened through this recent investment. These strategic steps demonstrate our commitment to effectively support our clients through all stages of product development and cGMP manufacturing to assure conformance to worldwide regulatory standards." added Mr. Pinto.

About Goodwin Biotechnology, Inc.Goodwin Biotechnologyis a uniquely qualified and flexible, US-based CDMO that offers a Single Source Solution to enhance the value of complex biopharmaceuticals for our clients. With over 26 years of experience as an independent integrated contract manufacturer, Goodwin Biotechnology has worked as a strategic partner with companies of all sizes from small university spin-offs to major research institutes, government agencies and large, established and multi-national biopharmaceutical companies. Based on the impressive track record, Goodwin Biotechnology has received numerous industry awards that span from Frost & Sullivan's Customer Value and Leadership Award for Best Practices in Mammalian Contract Manufacturing to the Biologics cGMP Manufacturer of the Year 2018 by Global Health & Pharma News. Click here to view the press releases! Additional information may be found at http://www.GoodwinBio.com.

For more information, please contact:

View original content:http://www.prnewswire.com/news-releases/goodwin-biotechnology-launches-a-digitization-initiative-by-investing-in-a-sophisticated-electronic-quality-solution-300953066.html

Read the original post:
Goodwin Biotechnology Launches a Digitization Initiative by Investing in a Sophisticated Electronic Quality Solution - Yahoo Finance

Read More...

Global Biotechnology Market 2019, Trend, CAGR Status, Growth, Analysis and Forecast to 2024 – BoundWatch

Sunday, November 10th, 2019

The company provides a detailed analysis of the market and future aspects of the Biotechnology Market. It focuses on critical and critical data that makes it a very important tool for research, experts, analysts, and managers to achieve ready-to-access analysis. The report provides an inclusive analysis of the Biotechnology market size forecast from 2018-2025.

Sample report can be viewed in a PDF form by visiting @ researchunt.com/report/global-biotechnology-market-size-status-and-forecast-2019-2025/#Free-Sample-Report

The report embraces the complete information of the key players involved in the worldwide Biotechnology market. In addition, it provides its market share by various regions with the company and product introduction and their position in the Biotechnology market. In addition, the report takes into account recent marketing developments as well as their marketing strategies along with an overall business overview. In addition, the report covers market growth factors and restraints of this market.

Prominent players of Biotechnology market:

Product Type Coverage (Market Size & Forecast, Major Company of Product Type etc.):

Application Coverage (Market Size & Forecast, Different Demand Market by Region, Main Consumer Profile etc.):

Regional Segmentation for Biotechnology market:

There are 10 chapters to put on view for Biotechnology market:

Chapter 1: Consumption by Regions

Chapter 2: Production, By Types, Revenue and Market share by Types

Chapter 3: Consumption, By Applications, Market share (%) and Growth Rate by Applications

Chapter 4: Complete profiling and analysis of Manufacturers

Chapter 5: Manufacturing cost analysis, Raw materials analysis, Region-wise manufacturing expenses

Chapter 6: Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 7: Marketing Strategy Analysis, Distributors/Traders

Chapter8: Market Effect Factors Analysis

Chapter9: Market Forecast

Chapter 10: Biotechnology Research Findings and Conclusion, Appendix, methodology and data source

Check here for the [emailprotected] researchunt.com/report/global-biotechnology-market-size-status-and-forecast-2019-2025/#Buying-Enquiry

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs.

View post:
Global Biotechnology Market 2019, Trend, CAGR Status, Growth, Analysis and Forecast to 2024 - BoundWatch

Read More...

The Week Ahead In Biotech: Smid-Cap Earnings Deluge, SITC Conference In The Spotlight – Benzinga

Sunday, November 10th, 2019

Biotech stocks extended their gains last week amid earnings news flow and the broader market strength. Large-cap pharma stocks saw particular strength.

Here are the key catalytic event a biotech investor should keep a tab on in the unfolding week.

The FDA is set to rule on Lipocine Inc (NASDAQ: LPCN)'s NDA for Tlando, or LPCN 1021 to treat hypogonadism in adult males. The PDUFA date is set for Saturday, Nov. 9.

Alkermes Plc (NASDAQ: ALKS) Phase 1/2 data for ALKS 4230 in solid tumors and ALKS 4230 in combination with Merck & Co., Inc. (NYSE: MRK)'s Keytruda in solid tumors.

Celldex Therapeutics, Inc. (NASDAQ: CLDX) Phase 1 data for CDX-1140 in solid tumors (Friday, Nov. 8).

Pieris Pharmaceuticals Inc (NASDAQ: PIRS) Phase 1/2 data for PRS-343 in HER2-positive solid tumors.

CELYAD SA/ADR (NASDAQ: CYAD) Phase 1 data for CYAD-01 and FOLFOX in colorectal cancer (Friday, Nov. 8) and Phase 1 data for CYAD-101 in colorectal cancer (Saturday, Nov. 9).

Heat Biologics Inc (NASDAQ: HTBX) Phase 2 data for HS-110 and Bristol-Myers Squibb Co (NYSE: BMY)'s Opdivo in non-small cell lung cancer (Friday).

Oncolytics Biotech, Inc. (NASDAQ: ONCY) - interim Phase 1b data for Pelareorep and Roche Holdings AG Basel ADR Common Stock (OTC: RHHBY)'s Tecentriq in breast cancer (Friday).

Nektar Therapeutics (NASDAQ: NKTR) updated Phase 1/2 data for NKTR-214 + Opdivo in multiple cancers (urothelial carcinoma, melanoma, renal cell carcinoma, and non-small cell lung cancer) (Saturday).

Mirati Therapeutics Inc (NASDAQ: MRTX) initial Phase 2 data for sitravatinib in urothelial carcinoma (Saturday).

Allena Pharmaceuticals Inc (NASDAQ: ALNA) Phase 2 data for reloxaliase, or ALLN-177, in primary hyperoxaluria and Phase 3 data for reloxaliase in enteric hyperoxaluria (Friday).

See Also: BTIG: Crispr Could Be A Takeover Target For Vertex

The earnings list is not comprehensive

Monday

Tuesday

Wednesday

Thursday

Friday

Galera Therapeutics has filed to offer 5 million shares in an IPO, with an estimated price range of $14-$16. The company has applied for listing its shares on the Nasdaq under the ticker symbol "GRTX."

89bio, a biotech company focusing on therapies for NASH and other metabolic disorders, is planning a 4.375-million IPO at an estimated price range of $15-17. The company has applied for listing its shares on the Nasdaq under the ticker symbol "ETNB."

Gene testing company Centogene is proposing to offer 4 million shares in an IPO, which are to be priced between $14 and $16. The company has applied to list the shares on the Nasdaq under the ticker symbol "CNTG."

CNS Pharmaceuticals, which develops therapies for brain cancer and other CNS tumors, has filed for a 2.125-million share IPO. The shares, which are likely to be priced in the range of $4-$5, are to be listed on the Nasdaq under the ticker symbol "CNSP."

Tela Bio, which sells soft tissue implants used in hernia repair and reconstructive surgery, is set to offer 4 million shares in an IPO, with each share to be priced between $14 and $16. The company seeks to list the shares on the Nasdaq under the ticker symbol "TELA."

BioNTech SE ADR (NASDAQ: BNTX)Vir Biotechnology Inc (NASDAQ: VIR)

2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Link:
The Week Ahead In Biotech: Smid-Cap Earnings Deluge, SITC Conference In The Spotlight - Benzinga

Read More...

Brokerages Anticipate Unity Biotechnology Inc (NASDAQ:UBX) Will Announce Earnings of -$0.49 Per Share – Slater Sentinel

Sunday, November 10th, 2019

Analysts expect that Unity Biotechnology Inc (NASDAQ:UBX) will report earnings of ($0.49) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Unity Biotechnologys earnings. Unity Biotechnology posted earnings of ($0.43) per share in the same quarter last year, which indicates a negative year over year growth rate of 14%. The firm is expected to announce its next earnings report after the market closes on Wednesday, November 6th.

On average, analysts expect that Unity Biotechnology will report full year earnings of ($2.02) per share for the current financial year, with EPS estimates ranging from ($2.07) to ($1.96). For the next year, analysts expect that the company will post earnings of ($2.09) per share, with EPS estimates ranging from ($2.25) to ($1.93). Zacks Investment Researchs earnings per share averages are an average based on a survey of research firms that follow Unity Biotechnology.

Unity Biotechnology (NASDAQ:UBX) last released its earnings results on Wednesday, August 7th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing analysts consensus estimates of ($0.44) by ($0.10).

Institutional investors and hedge funds have recently made changes to their positions in the company. Aperio Group LLC acquired a new position in shares of Unity Biotechnology during the 2nd quarter worth $50,000. Citadel Advisors LLC grew its stake in Unity Biotechnology by 449.0% in the 2nd quarter. Citadel Advisors LLC now owns 238,386 shares of the companys stock valued at $2,265,000 after buying an additional 194,965 shares during the last quarter. Ellington Management Group LLC acquired a new position in Unity Biotechnology in the 2nd quarter valued at $103,000. BlackRock Inc. grew its stake in Unity Biotechnology by 5.0% in the 2nd quarter. BlackRock Inc. now owns 1,992,613 shares of the companys stock valued at $18,929,000 after buying an additional 94,183 shares during the last quarter. Finally, Virtus ETF Advisers LLC grew its stake in Unity Biotechnology by 84.8% in the 2nd quarter. Virtus ETF Advisers LLC now owns 30,554 shares of the companys stock valued at $290,000 after buying an additional 14,021 shares during the last quarter. Institutional investors own 38.32% of the companys stock.

UBX stock opened at $6.88 on Friday. Unity Biotechnology has a 12-month low of $5.61 and a 12-month high of $17.46. The company has a market cap of $295.51 million, a price-to-earnings ratio of -2.71 and a beta of -0.19. The company has a 50 day moving average of $6.81 and a two-hundred day moving average of $7.63.

About Unity Biotechnology

Unity Biotechnology, Inc, a biotechnology company, engages in the research and development of therapeutics to extend human health span. The company's lead drug candidates include UBX0101 that is in Phase 1 clinical study for musculoskeletal disease; and UBX1967 for ophthalmologic diseases. It is also developing programs in pulmonary disorders.

Read More: Dollar Cost Averaging

Get a free copy of the Zacks research report on Unity Biotechnology (UBX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Unity Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unity Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.

Read more from the original source:
Brokerages Anticipate Unity Biotechnology Inc (NASDAQ:UBX) Will Announce Earnings of -$0.49 Per Share - Slater Sentinel

Read More...

Puma Biotechnology to Present at the Credit Suisse Healthcare Conference – Yahoo Finance

Sunday, November 10th, 2019

LOS ANGELES--(BUSINESS WIRE)--

Puma Biotechnology, Inc. (PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 10:55 a.m. MST (9:55 a.m. PST, 12:55 p.m. EST) on Tuesday, November 12, at the Credit Suisse 28th Annual Healthcare Conference. The conference will be held at The Phoenician Resort in Scottsdale, Arizona.

A live webcast of the presentation will be available on the Companys website at http://www.pumabiotechnology.com. The presentation will be archived on the website and available for 30 days.

About Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights to three drug candidates PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration in July 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX (neratinib) tablets. NERLYNX was granted marketing authorization by the European Commission in September 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX is a registered trademark of Puma Biotechnology, Inc.

Further information about Puma Biotechnology can be found at http://www.pumabiotechnology.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191104005169/en/

Original post:
Puma Biotechnology to Present at the Credit Suisse Healthcare Conference - Yahoo Finance

Read More...

Generex Biotechnology Provides Guidance: Form 10k Annual Report will be filed Tuesday Morning November 12th 2019 – Yahoo Finance

Sunday, November 10th, 2019

MIRAMAR, Fla., Nov. 08, 2019 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (GNBT) is pleased to announce that its 10k annual report will be filed Tuesday morning within the time afforded to public companies under the standard filing extension. Generex has received many calls in regard to this very important filing, and the company wants to assure everyone that the report has been completed, and the filing is definitive for Tuesday, November 12, 2019.

Joe Moscato, CEO and President commented, I appreciate everyones concern in this important filing as we march towards our NASDAQ listing. This annual report filing was much more complicated than last years report due to the many acquisitions the company made over the last year, which required that the financial audit be reviewed by multiple audit firms. Further, this is the first full audit that our new auditors have had to complete, so understanding all of Generex 23-year history of business, and the complexities of the MSO and healthcare initiatives that the company has initiated was no small task. Now that this first 10K audit has been completed for the NuGenerex family of companies, our financial accounting and auditing work will get easier, having been streamlined for the future with standard operating procedures.

About Generex Biotechnology Corp.

Generex Biotechnology is an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapies. Generex is building a new kind of healthcare company that extends beyond traditional models providing support to physicians in an MSO network, and ongoing relationships with patients to improve the patient experience and access to optimal care.

In addition to advancing a legacy portfolio of immune-oncology assets, medical devices, and diagnostics, the Company is focused on an acquisition strategy of strategic businesses that complement existing assets and provide immediate sources of revenue and working capital. Recent acquisitions include a management services organization, a network of pharmacies, clinical laboratory, and medical device companies with new and approved products.

Cautionary Note Regarding Forward-Looking Statements

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should," "subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

Generex Contact:

Generex Biotechnology Corporation

Joseph Moscato 646-599-6222

Todd Falls 1-800-391-6755 Extension 222investor@generex.com

Read the rest here:
Generex Biotechnology Provides Guidance: Form 10k Annual Report will be filed Tuesday Morning November 12th 2019 - Yahoo Finance

Read More...

Puma Biotechnology Licensing Partner CANbridge Pharmaceuticals Receives Registration Approval in Hong Kong for NERLYNX (neratinib) for Extended…

Sunday, November 10th, 2019

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (Nasdaq: PBYI) announced that its licensing partner in Greater China, CANbridge Pharmaceuticals Inc., has received registration approval from the Department of Health in Hong Kong to market NERLYNX (neratinib) for the extended adjuvant treatment of adult patients with early stage hormone receptor positive HER2-overexpressed/amplified breast cancer and who have completed adjuvant trastuzumab-based therapy less than one year ago.

The rapid and smooth advancement of NERLYNX through the Hong Kong regulatory process to market approval is a testament to the quality of our regulatory expertise, and the CANbridge commitment to bring new treatments to underserved patient populations in greater China, said James Xue, PhD, Founder, Chairman and CEO, CANbridge Pharmaceuticals. With this first targeted therapy approved in our oncology platform, CANbridge is able to provide women in Hong Kong, with HER2-positive breast cancer at risk of recurrence, a new and vital treatment option shortly after approval in the West.

Alan H. Auerbach, Puma Biotechnologys Chairman, Chief Executive Officer and President, added, This registration approval through our partnership with CANbridge represents an important market entry for us as we execute on our global commercial strategy. CANbridge has the commercial infrastructure and resources to provide NERLYNX to patients in the region.

About HER2-Positive Breast Cancer

Approximately 20 to 25 percent of breast cancer tumors over-express the HER2 protein. HER2-positive breast cancer is often more aggressive than other types of breast cancer, increasing the risk of disease progression and death. Although research has shown that trastuzumab can reduce the risk of early stage HER2-positive breast cancer returning after surgery, up to 25% of patients treated with trastuzumab experience recurrence.

About CANbridge Pharmaceuticals

CANbridge Pharmaceuticals Inc. is a China-based biopharmaceutical company accelerating development and commercialization of specialty healthcare products for orphan diseases and targeted cancers, focusing on products that are unavailable or address medical needs that are underserved in the region. CANbridge has been widely recognized as a leader in orphan diseases in China. It has a global partnership with WuXi Biologics to develop and commercialize proprietary therapeutics for the treatment of rare genetic diseases. In addition, it has an exclusive licensing agreement to commercialize Hunterase, an enzyme replacement therapy for the treatment of Hunter syndrome, developed by GC Pharma and marketed in more than ten countries worldwide. CANbridge also has an oncology portfolio, which includes exclusive rights to develop and commercialize Puma Biotechnologys NERLYNX (neratinib), approved in the United States, and rights to other novel candidates.

About Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration in July 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX (neratinib) tablets. NERLYNX was granted marketing authorization by the European Commission in August 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX is a registered trademark of Puma Biotechnology, Inc.

Further information about Puma Biotechnology may be found at http://www.pumabiotechnology.com.

Important Safety Information Regarding NERLYNX (neratinib) U.S. Indication

NERLYNX (neratinib) tablets, for oral use

INDICATIONS AND USAGE: NERLYNX is a kinase inhibitor indicated for the extended adjuvant treatment of adult patients with HER2 overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy.

CONTRAINDICATIONS: None

WARNINGS AND PRECAUTIONS:

ADVERSE REACTIONS: The most common adverse reactions ( 5%) were diarrhea, nausea, abdominal pain, fatigue, vomiting, rash, stomatitis, decreased appetite, muscle spasms, dyspepsia, AST or ALT increase, nail disorder, dry skin, abdominal distention, weight decreased and urinary tract infection.

To report SUSPECTED ADVERSE REACTIONS, contact Puma Biotechnology, Inc. at 1-844-NERLYNX (1-844-637-5969) and http://www.NERLYNX.com or FDA at 1-800-FDA-1088 or http://www.fda.gov/medwatch.

DRUG INTERACTIONS:

USE IN SPECIFIC POPULATIONS:

Please see Full Prescribing Information for additional safety information.

The recommended dose of NERLYNX is 240 mg (six 40 mg tablets) given orally once daily with food, continuously for one year. Antidiarrheal prophylaxis should be initiated with the first dose of NERLYNX and continued during the first 2 months (56 days) of treatment and as needed thereafter.

To help ensure patients have access to NERLYNX, Puma has implemented the Puma Patient Lynx support program to assist patients and healthcare providers with reimbursement support and referrals to resources that can help with financial assistance. More information on the Puma Patient Lynx program can be found at http://www.NERLYNX.com or 1-855-816-5421.

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding the worldwide expansion of NERLYNX. All forward-looking statements involve risks and uncertainties that could cause Pumas actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors, which include, but are not limited to, the risk factors disclosed in the periodic and current reports filed by Puma with the Securities and Exchange Commission from time to time, including Pumas Annual Report on Form 10-K for the year ended December 31, 2018. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Puma assumes no obligation to update these forward-looking statements, except as required by law.

Continued here:
Puma Biotechnology Licensing Partner CANbridge Pharmaceuticals Receives Registration Approval in Hong Kong for NERLYNX (neratinib) for Extended...

Read More...

PDS Biotechnology Accepted for Oral Presentation at the 34th Annual Society for Immunotherapy of Cancer Annual Meeting – Yahoo Finance

Sunday, November 10th, 2019

Dr. Lauren V. Wood, M.D. to present data from the companys phase 1 PDS0101 human trial demonstrating potent antigen-specific CD8+ T-cell responses in-vivo

PRINCETON, N.J., Nov. 06, 2019 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (PDSB), a clinical-stage immuno-oncology company developing multiple therapies based on the companys proprietary Versamune T-cell activating technology , today announced that Lauren V. Wood, M.D., Chief Medical Officer of PDS Biotechnology, has been selected to make an oral presentation reporting on the study design and clinical data from its previously announced Phase 1 study of PDS0101 at the Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting, taking place on November 7-10, 2019 in National Harbor, Maryland.

In addition to the immunogenicity and safety data from the Phase 1 study of PDS0101, we are very pleased to highlight follow-up data, demonstrating the translation of our Versamune-induced immunological mechanisms from animal to human studies in an oral presentation at the 34th annual SITC meeting, commented Lauren V. Wood, M.D., PDS Biotechnologys Chief Medical Officer. Based on this encouraging data, we are now focused on initiating three Phase 2 studies in the first quarter of 2020. These include our previously announced combination study to evaluate PDS0101 in combination with KEYTRUDA in the treatment of HPV16 positive head and neck cancer, a study to evaluate PDS0101 in combination with two immunotherapies in advanced HPV-associated cancers with the National Cancer Institute and a study, the details of which are included in our supplemental corporate presentation filed on October 29, 2019, to evaluate the combination of PDS0101 and chemoradiotherapy in patients with locally advanced cervical cancer.

Details for the oral presentation are below:

Abstract 017: A Novel Enantio-Specific Cationic Lipid R-DOTAP + HPV16 E6 & E7 Antigens Induces Potent Antigen-Specific CD8+ T Cell Responses In-Vivo in Subjects with CIN and High-Risk Human Papilloma Virus InfectionPresenter: Dr. Lauren V. Wood, M.D., Chief Medical Officer, PDS BiotechnologySession Title: Session 209: Virus Driven CancersDate: Friday, November 8th, 2019Time: 6:00 6:10pm ET

Full data from the Phase 1 study can be found in the supplemental corporate presentation filed on October 29, 2019.

About PDS Biotechnology

PDS Biotechnology is a clinical-stage immuno-oncology company developing multiple therapies based on the companys proprietary Versamune T-cell activating technology platform. The Versamune platform effectively delivers tumor-specific antigens for in-vivo uptake and processing, while also activating a critical immunological pathway, the type 1 interferon pathway, thus resulting in the production of potent tumor-specific killer T-cells. Using Versamune, PDS Biotechnology is engineering therapies designed to better recognize cancer cells and break down their defense systems to effectively attack and destroy tumors. PDS Biotechnologys pipeline combines the Versamune technology with tumor-specific antigens across several cancer types. To learn more, please visit http://www.pdsbiotech.com.

About PDS0101

PDS Biotechnologys lead candidate, PDS0101, combines the utility of the Versamune platform with targeted antigens in HPV-expressing cancers. In partnership with Merck and the National Cancer Institute (NCI), PDS Biotechnology is advancing PD0101 to Phase 2 studies in head and neck cancer and in HPV-related advanced cancer.

Forward Looking StatementsThis communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the Company) and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Companys management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as may, will, should, would, expect, anticipate, plan, likely,believe,estimate,project,intend,and other similar expressions among others. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the ability of the Company to integrate Edge and PDS Biotechnology following the merger; the Companys ability to protect its intellectual property rights; competitive responses to the completion of the merger; potential adverse reactions or changes to business relationships resulting from the completion of the merger;the Companys anticipated capital requirements, including the Companys anticipated cash runway and the Companys current expectations regarding its plans for future equity financings; the timing for the Company or its partners to initiate the planned clinical trials for its lead assets, PDS0101 and PDS0102; the Companys interpretation of the results of its Phase 1 trial for PDS0101 and whether such results are sufficient to support additional trials or the future success of such trials;the successful implementation of the Companys research and development programs and collaborations; the acceptance by the market of the Companys product candidates, if approved;the timing of and the Companys ability to obtain and maintainU.S. Food and Drug Administrationor other regulatory authority approval of, or other action with respect to, the Companys product candidates;and other factors, including legislative, regulatory, political and economic developmentsnot within the Companys control. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors included in the Companys annual and periodic reports filed with the SEC. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

Story continues

Read the original post:
PDS Biotechnology Accepted for Oral Presentation at the 34th Annual Society for Immunotherapy of Cancer Annual Meeting - Yahoo Finance

Read More...

Video: ‘Blood on their hands’Greens’ resistance to biotechnology blocks sustainable agriculture, climate change innovation, says GLP’s Jon Entine -…

Thursday, October 31st, 2019

Green advocacy groups, mostly based in Europe, are the single biggest impediment to sustainable agriculture, said GLP executive director Jon Entine in an interview with Marcel Bruins, editorial director of European Seed magazine and website.

CRISPR and other gene-editing and New Breeding Techniques are fast being adopted around the world, although many environmental activist groups are doing their best to frighten the public and intimidate legislators into erecting insurmountable regulatory barriers. Theyve been largely successful in Europe, which is blocking gene-edited crops under legislation passed in the pre-CRISPR era in 2001, Entine said, but the rest of the world is more open to the innovations.

Entine was interviewed in mid-October at the annual Euroseeds Congress 2019, held in Stockholm.

The GLP founder raised a range of challenges facing agriculture in the face of what can only be called a determined anti-technology faction. Africa appears to be emerging as a central battleground. Europe has strong historical trade and cultural ties to the continent. It has long used those connections to push its anti-GMO policies. Africa is now rebelling, Entine noted, and is pursuing biotechnology innovation led by African scientists, particularly focusing on animal biotech, in an attempt to shed Europes yoke.

Its an uphill battle for Europe and Africa, Entine noted. Activist groups, mostly from European nations, are going door-to-door, telling Africans deliberate falsehoods about biotechnology, claiming that genetically engineered crops cause cancer and sterility.

Entine went on to offer a communications strategy to give the science a chance, so crop biotechnology has an opportunity to succeed on its merits, without being tangled in Europes ideological web.

Jon Entine is the founder and executive director of the Genetic Literacy Project. Twitter: @jonentine.

Read more:
Video: 'Blood on their hands'Greens' resistance to biotechnology blocks sustainable agriculture, climate change innovation, says GLP's Jon Entine -...

Read More...

Partners Capital Shines the Spotlight on Geopolitics, China, Biotechnology and Impact Investing at Its Fourth Annual Investor Workshop – PRNewswire

Thursday, October 31st, 2019

In attendance at the Park Hyatt Hotel in Midtown Manhattan, were approximately 140 guests, predominately from the US, but also from across Europe, the Middle East, Asia as well as Australia. Partners Capital's client base of investment professionals, institutional clients and family offices were all represented. This included investment committee members from New York University School of Law, the Los Angeles Museum of Contemporary Art, Singapore educational endowments and INSEAD Business School.

The afternoon started with Stan Miranda, Chief Executive Officer of Partners Capital, describing the overarching theme of the Client Workshop being de-globalization, with four underlying sub-themes - geopolitics, China, biotechnology and impact investing. "While Globalization has been a strong force in the past, lifting people out of poverty and bringing the world closer together, there are serious headwinds. Given these headwinds, we face a question of whether investors should concentrate their investments more domestically or seek opportunities out of new economic alliances that are likely to form?" The afternoon provided arguments on multiple sides.

Internal speakers were joined by three experts:

Matthew Gertken, Geopolitical Strategist at BCA Researchspoke on geopolitics' impact on investment strategy going forward. BCA research concludes that the US will be in at least a decade-long economic "cold war" with China. Any trade deals between now and Trump's re-election will be temporary stop-gaps distracting investors from the real changes in the form of deeper alliances between China and its historical and new allies; and between the US and its historical allies.

Jason Tan, Chief Investment Officer from Jeneration Capitallaid out the facts surrounding the technology arms race between China and the US, highlighting the very different strategies Chinese tech leaders are following versus US tech leaders. These companies initially start with one online business and subsequently expand into additional segments (e.g., content & media, social & messaging, mobile payments), funding start-ups to create new innovations so they do not have to themselves. The integrated ecosystem approach is highlighted by the fact that China is home to a disproportionate number of the "super" unicorns ($15B+ valued companies).

Behzad Aghazadeh, Managing Partner at Avoro Capitalspoke on the future biotechnology breakthroughs saying that "today we are benefitting from the groundwork of decades of research that can now be widely applied to medicine.breakthroughs in cancer are accelerating as we continue to see advances in treatments for previously uncurable indications. Today there are 16,000 ongoing pipeline projects, up from 6,000 in 2001, which provides a strong platform of ongoing innovation in the sector".Stan Miranda added his own comments on investing in the public biotech sector - "There are 1,200 public biotech companies today, only 5% of which have revenue and 75% have not yet reached phase III drug trials. By investing with firms like Avoro, we expect to see venture capital like returns from this liquid public sector of the public equity markets."

Partners Capital presentations included two four-person panel sessions featuring the Partners Capital CIO's and Asset Class Heads, addressing Client Portfolio Strategy Choices and Asset Class Strategies going forward, respectively.

- Will Fox, Partner, Head of North America, Boston - spoke on the right illiquidity budget

- John Collis, Partner, Head of Europe, London spoke on tactical asset allocation

- Elizabeth Trotta, Managing Director, New York covered our recession playbook

- David Shushan, Partner, Boston discussed technology sector over-weights

- Alex Band, Managing Director, Head of Public Equities, Boston

- Rich Scarinci, Partner, Absolute Return & Credit, Boston

- Suzanne Streeter, Partner, Head of Private Markets, Boston

- Emma Bewley, Principal, Private Debt, London

The audience responded most to Elizabeth Trotta's run-through of the "Partners Capital Recession Playbook", which is already in place in most client portfolios. But the key message of the internal presentations was how Partners Capital believes that a highly diversified, risk-managed multi-asset class portfolio is the best long term defense against an economic downturn.

The afternoon's final session, Impact Investing, featured a short video of Sir Ronald Cohen, filmed specifically for the event, addressing the importance of social impact investing and why investors should be focusing not only on risk and return but also on optimizing the impact of their investments on society and the environment. Euan Finlay, Partner and Chair of Partners Capital's Responsible Investing Committee, then went on to discuss the firm's responsible investing framework for implementing and reporting on responsible investing in client portfolios.

Paul Dimitruk, Chairman of Partners Capital, closed the day focusing on the firm's desire to be not just an advisor, but a "thought-partner" on each client's investment journey. He implored each client to continue to challenge and push Partners Capital to be the best it can be. "Our mission is to do go beyond just asset allocation and manager selection, but to help discern where risk and return are, and where value is created or destroyed."

About Partners Capital

Founded in 2001, Partners Capital is a wholly independent Outsourced Investment Office (OCIO) primarily serving sophisticated institutions and senior investment professionals inEurope,North AmericaandAsia. With offices inBoston,New York,San Francisco, London, Singapore and Paris, the firm is one of the few truly global OCIOs, employing 175 people worldwide and covering all major asset classes. The firm oversees assets of more than$27 billion. Its institutional clients include a number of Oxford and Cambridge Colleges,Eton College, INSEAD business school, the Research Foundation for theState of New York'sUniversity System, the Royal Academy of Arts, Milton Academy, the Hong Kong Cancer Fund and the Cancer Research Institute. Additional information on Partners Capital may be found athttp://www.partners-cap.com.

Photo: https://mma.prnewswire.com/media/1019263/Partners_Capital_AIW_Image.jpg Logo: https://mma.prnewswire.com/media/817400/Partners_Capital_Logo.jpg

SOURCE Partners Capital

Home

See the rest here:
Partners Capital Shines the Spotlight on Geopolitics, China, Biotechnology and Impact Investing at Its Fourth Annual Investor Workshop - PRNewswire

Read More...

Page 41«..1020..40414243..5060..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick